Syndax Pharmaceuticals
Stock Forecast, Prediction & Price Target
Syndax Pharmaceuticals (SNDX) stock Price Target by analysts
$27.5
Potential upside: 72.41%
Syndax Pharmaceuticals price prediction
What is Syndax Pharmaceuticals stock analysts` prediction?
Syndax Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Syndax Pharmaceuticals in the last 3 months, the avarage price target is $27.5, with a high forecast of $NaN. The average price target represents a 72.41% change from the last price of $15.95.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Syndax Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Syndax Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
George Farmer Scotiabank | 0% 0/1 | 10 months ago | $18 12.85% upside | $20.04 | StreetInsider | Previous targets (0) |
David Dai UBS | 0% 0/1 | 11 months ago | $37 131.97% upside | $18.54 | StreetInsider | Previous targets (0) |
Yigal Nochomovitz Citigroup | 0% 0/1 | about 1 year ago | $34 113.16% upside | $20.09 | StreetInsider | Previous targets (0) |
Peter Lawson Barclays | 0% 0/1 | about 1 year ago | $33 106.89% upside | $19.58 | TheFly | Previous targets (0) |
Jason Zemansky Bank of America Securities | 0% 0/2 | about 1 year ago | $31 94.35% upside | $19.58 | TheFly | Previous targets (1) |
Jason Zemansky Bank of America Securities | 0% 0/2 | about 1 year ago | $30 88.08% upside | $21.99 | StreetInsider | Previous targets (1) |
Kelly Shi Jefferies | 0% 0/1 | about 1 year ago | $37 131.97% upside | $20.32 | StreetInsider | Previous targets (0) |
Bradley Canino Stifel Nicolaus | 0% 0/1 | over 1 year ago | $40 150.78% upside | $22.38 | StreetInsider | Previous targets (0) |
Unknown J.P. Morgan | N/A | over 2 years ago | $41 157.05% upside | $26.33 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | over 2 years ago | $33 106.89% upside | $20.64 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 2 years ago | $39 144.51% upside | $23.39 | Benzinga | N/A |
Syndax Pharmaceuticals Financial Estimates
Syndax Pharmaceuticals Revenue Estimates
Syndax Pharmaceuticals EBITDA Estimates
Syndax Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $139.70M N/A | $0 -100% | $0 0% | Avg: $115.24M Low: $89.38M High: $175.38M avg. 0% | Avg: $237.30M Low: $135.90M High: $466.44M avg. 105.91% | Avg: $370.32M Low: $212.08M High: $727.91M avg. 56.05% | Avg: $514.36M Low: $294.57M High: $1.01B avg. 38.89% |
Net Income
% change YoY
| $24.92M N/A | $-143.74M -676.70% | $-209.36M -45.64% | Avg: $-263.87M Low: $-275.14M High: $-75.29M avg. -26.03% | Avg: $-193.66M Low: $-189.29M High: $-59.11M avg. 26.60% | Avg: $-73.04M Low: $-164.73M High: $-32.46M avg. 62.28% | Avg: $-22.28M Low: $-50.25M High: $-9.90M avg. 69.49% |
EBITDA
% change YoY
| $26.22M N/A | $-151.75M -678.78% | $-229.94M -51.51% | Avg: $4.32M Low: $3.35M High: $6.58M avg. 101.88% | Avg: $8.90M Low: $5.10M High: $17.50M avg. 105.91% | Avg: $13.90M Low: $7.96M High: $27.32M avg. 56.05% | Avg: $19.30M Low: $11.05M High: $37.94M avg. 38.89% |
EPS
% change YoY
| $0.48 N/A | -$2.37 -593.75% | -$2.98 -25.73% | Avg: -$2.88 Low: -$3.91 High: -$1.07 avg. 3.38% | Avg: -$2.02 Low: -$2.69 High: -$0.84 avg. 29.85% | Avg: -$1.04 Low: -$2.34 High: -$0.46 avg. 48.60% | Avg: -$0.32 Low: -$0.71 High: -$0.14 avg. 69.49% |
Operating Expenses
% change YoY
| $113.48M N/A | $151.75M 33.71% | $229.95M 51.52% | Avg: $636.23M Low: $493.47M High: $968.24M avg. 176.67% | Avg: $1.31B Low: $750.28M High: $2.57B avg. 105.91% | Avg: $2.04B Low: $1.17B High: $4.01B avg. 56.05% | Avg: $2.83B Low: $1.62B High: $5.58B avg. 38.89% |
FAQ
What is Syndax Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 33.08% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -275.14M, average is -263.87M and high is -75.29M.
What is Syndax Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 50.21% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $89.38M, average is $115.24M and high is $175.38M.
What is Syndax Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 37.83% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$3.91, average is -$2.88 and high is $-1.07.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Syndax Pharmaceuticals stock. The most successful analyst is George Farmer.